CliffBio
biologic

Acam2000

Smallpox (Vaccinia) Vaccine, Live

Loss of exclusivityAugust 2019projected — 12-year biologic exclusivity estimate
CompanyEmergent Product Development Gaithersburg →See this company's full patent-cliff portfolio

Drug detail

Brand nameAcam2000
Active ingredientSmallpox (Vaccinia) Vaccine, Live
Strength1.0- 5.0 X 10^8 PFU/ML
Dosage formSuspension
RoutePercutaneous
ModalityBiologic
FDA approvalAugust 2007
Marketing statusRx

More from Emergent Product Development Gaithersburg

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Acam2000 patent cliff — loss of exclusivity August 2019 | CliffBio